IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3308 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed7611    
    Printed152    
    Emailed17    
    PDF Downloaded412    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 STUDIES
Year : 2003  |  Volume : 69  |  Issue : 6  |  Page : 396--400

Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: A multicentric, open label, phase III study


1 Department of Dermatology, G. T. Hospital, Grant Medical College, Mumbai 400001, India
2 Department of Skin, Rajeev Gandhi Medical College & Chhatrapati Shivaji Maharaj Hospital, Kalwa, India
3 Pramila Hospital , Sneha Polyclinic & I.C.C.U., Manisha Nagar, Old Mumbai Poona Road, Kalwa, Thane 400605, India
4 Department of Dermatology, M. R. Medical College, Gulbarga, India
5 Zubeda Hospital, Chennai, India
6 B. R. Hospital, Chennai, India
7 Glenmark Pharmaceuticals Limited, 801-813, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400026, India

Correspondence Address:
N Dongre
Glenmark Pharmaceuticals Limited, 801-813, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400026
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17642950

Rights and PermissionsRights and Permissions

AIM OF STUDY: Tacrolimus, a topical immunomodulator, has been introduced as a new treatment for moderate to severe atopic dermatitis. The present study was conducted to evaluate the efficacy, safety and tolerability of Tacrolimus ointment in patients of atopic dermatitis in an Indian setting. METHODS: The present study was a prospective, open, multicentric, Phase III trial.The duration of study was 5 weeks, including a 3-week active treatment period, preceded by a 1-week washout phase and followed by a 1-week follow-up phase. Patients diagnosed to be suffering from moderate to severe atopic dermatitis as per the Rajka and Langeland criteria were treated with Tacrolimus ointment 0.03% twice daily. Efficacy was assessed by modified Eczema Area Sensitivity Index (mEASI) score, patient's and physician's global assessment. Tolerability and safety was assessed by physical examination, laboratory parameters and evaluation of adverse events. RESULTS: There was a statistically significant decrease in the modified Eczema Area Sensitivity Index (mEASI) score (P<0.05). Patient's and Physician's global evaluation of treatment was complete resolution to very good improvement in most of the patients. The laboratory values were within normal limits. The drug was well tolerated. CONCLUSIONS: This study confirms the efficacy and safety of Tacrolimus ointment 0.03% in Indian patients of moderate to severe atopic dermatitis.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow